Fig. 1From: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samplesLiquid biopsy, non invasive and low-risk procedure, allows to monitor the changing and evolving landscape of cancer in real-time during the course of disease. In blood vessels, circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), non-coding RNAs, circulating tumor cells (CTCs), and circulating leukocytes represent promising biomarkers to assess tumor heterogeneity and patients’ treatment responseBack to article page